Hepatitis B and Hepatitis C Life Insurance Ratings

Hepatitis B and Hepatitis C are among the most nuanced conditions in life insurance underwriting. The key insight: outcomes have improved dramatically — especially for Hepatitis C, where modern direct-acting antiviral (DAA) therapy can achieve a sustained virologic response (SVR), essentially a functional cure. Applicants with Hep C post-SVR, or Hep B carriers with normal liver function, can qualify for coverage at table ratings or, in favorable cases, standard rates at select carriers.

What Underwriters Evaluate for Hepatitis B & C

Underwriters look well beyond the diagnosis itself. Key factors that drive outcomes include:

Hepatitis Type (A, B, or C) — Hepatitis A that has fully resolved is a non-event in underwriting. Hepatitis B and C require detailed evaluation. Chronic Hepatitis B (HBsAg positive for 6+ months) is rated differently from resolved Hepatitis B (HBsAb positive). Hepatitis C is evaluated based on treatment history and current viral status.

Liver Function Tests (LFTs) — This is the most critical data point for both Hep B and Hep C. Underwriters review ALT, AST, alkaline phosphatase, bilirubin, albumin, and platelet count. Normal or near-normal LFTs indicate the liver is functioning well. Elevated enzymes signal active inflammation or progressive liver disease.

Hepatitis C SVR (Sustained Virologic Response) — For Hep C patients who have completed DAA treatment (Harvoni, Epclusa, Mavyret, etc.) and achieved SVR (undetectable HCV RNA 12 weeks post-treatment), underwriting outcomes have improved dramatically. Post-SVR applicants with normal LFTs are now among the most favorable Hep C profiles underwriters will see.

Viral Load (Hepatitis C) — For untreated Hep C patients, viral load indicates how active the infection is. High viral load with elevated LFTs indicates progressive disease. Low viral load alone is insufficient — LFTs and liver biopsy results are needed to fully assess risk.

Hepatitis B Surface Antigen vs. Antibody Status — HBsAg positive = chronic carrier or active infection. HBsAb positive = resolved infection or vaccination immunity. Chronic carriers with normal LFTs and low viral replication (HBV DNA) are underwritten differently from those with active replication and elevated LFTs.

Fibrosis and Cirrhosis Staging — Liver biopsy or non-invasive fibrosis scores (FibroScan, FIB-4, APRI) are critical. No fibrosis or mild fibrosis (F0–F1) is viewed very favorably. Moderate fibrosis (F2–F3) results in higher ratings. Cirrhosis (F4) dramatically increases ratings and may lead to a decline, particularly if decompensated.

Alcohol Use — Alcohol is a significant accelerant of liver damage in hepatitis patients. Any history of alcohol use or abuse is viewed very negatively. Underwriters want evidence of reduced or eliminated alcohol consumption and ideally a documented multi-year alcohol-free history.

Treatment History and Compliance — For Hep C, completed DAA therapy with SVR is the gold standard. For Hep B, antiviral therapy (tenofovir, entecavir) to suppress viral replication is viewed positively. Refusal of recommended treatment or non-compliance raises serious concerns.

Co-Morbid Conditions — HIV co-infection, diabetes, obesity, or other serious health conditions compound the risk significantly. Hep C or Hep B combined with HIV is typically a decline at traditional fully-underwritten carriers.

Carrier Guidelines: Hepatitis B & C Underwriting Comparison

The table below reflects how major carriers generally approach hepatitis underwriting. Post-SVR Hep C and well-managed Hep B carriers represent the most favorable profiles.

Carrier	Hep C — Post-SVR, Normal LFTs	Hep C — Untreated / Active	Hep B — Chronic Carrier, Normal LFTs	Hep B or C with Cirrhosis
Protective Life	Standard to Table 2 (best cases Standard with 2+ yrs post-SVR, normal LFTs, no fibrosis)	Table 4–8 depending on LFTs and fibrosis	Table 2–4 with normal LFTs, low viral replication	Compensated: Table 8+ or Decline; Decompensated: Decline
Banner Life / Legal & General	Standard to Table 2 post-SVR with clean labs	Table 4–8 or Decline	Table 2–4	Decline in most cases
Prudential	Standard possible for post-SVR 2+ yrs, no fibrosis, normal LFTs; otherwise Table 2–4	Table 4–8 or Decline	Table 2–4 with normal liver function	Decline
Pacific Life	Standard to Table 2 post-SVR	Table 4–8 or Decline	Table 2–4	Decline
North American Company	Table 2–4 post-SVR; Standard possible for best cases	Table 4–8 or Decline	Table 2–4	Decline
Mutual of Omaha	Table 2–4 post-SVR; Standard possible for ideal profiles	Table 4–8 or Decline	Table 2–4	Decline
Lincoln Financial	Table 2–4 post-SVR	Table 4–8 or Decline	Table 2–4 with normal LFTs	Decline
Transamerica	Table 2–4 post-SVR; Standard possible in best cases	Table 4–8 or Decline	Table 2–4 with normal liver function	Decline

Guidelines current as of 2025–2026. Carrier underwriting guidelines are subject to change. Verify with us before applying.

Presentations/Situations That Are Typically Declined

Certain hepatitis presentations create significant barriers at traditional fully-underwritten carriers:

Decompensated Cirrhosis — Cirrhosis with complications such as ascites, spontaneous bacterial peritonitis, variceal bleeding, or hepatic encephalopathy (Child-Pugh class B or C) is a decline at virtually all traditional carriers. Guaranteed issue products remain an option.

Active Hepatitis C with Elevated LFTs and No Treatment — Untreated, active Hep C with elevated liver enzymes signals ongoing liver damage. Most carriers will either decline or significantly table rate these applicants until treatment is initiated and SVR is achieved.

Hepatitis B with Active Replication and Elevated LFTs — HBsAg positive with detectable HBV DNA and abnormal liver enzymes indicates active viral replication causing liver injury. This is a serious risk profile and typically results in high table ratings or a decline.

Hepatocellular Carcinoma (Liver Cancer) — Any history of or active hepatocellular carcinoma (HCC), a known complication of chronic Hepatitis B or C, is a decline at all traditional carriers. This requires specialized products.

HIV Co-Infection — Hepatitis B or C co-infection with HIV dramatically increases the mortality risk and is a decline at most traditional fully-underwritten carriers. Some specialized carriers may consider such cases individually, but acceptance is rare.

Ongoing Alcohol Use — Any current or recent alcohol use in a hepatitis patient is a significant barrier to coverage. Alcohol greatly accelerates liver fibrosis and cirrhosis progression. Underwriters may decline applicants with a history of alcohol abuse combined with chronic hepatitis, even if LFTs are currently normal.

Advanced Fibrosis (F3–F4) — Liver biopsy or FibroScan results showing F3 (bridging fibrosis) or F4 (cirrhosis) indicate significant structural liver damage. F3 results in high table ratings; F4 typically results in a decline at most carriers regardless of current LFT levels.

What You Can Do to Improve Your Outcome

Get Treated for Hepatitis C (If Untreated) — Modern DAA therapy (Harvoni, Epclusa, Mavyret) achieves SVR in 95%+ of cases with an 8–12 week treatment course. Achieving SVR and waiting 12–24 months post-treatment with normal LFTs is the single most impactful action a Hep C patient can take to improve their underwriting outcome.

Keep Liver Function Tests Current and Normal — Having recent (within 6–12 months) LFT results showing normal or near-normal enzyme levels is critically important. Underwriters want to see a trend of stable or improving liver function, not just a single data point.

Complete a FibroScan or Liver Biopsy — Having documented fibrosis staging (F0–F1) is a major positive underwriting factor. If you haven’t had a FibroScan or liver biopsy recently, obtaining one showing no significant fibrosis can meaningfully improve your offer.

Eliminate Alcohol Completely — Even moderate alcohol use is viewed negatively for hepatitis patients. A documented alcohol-free history of 2+ years, supported by your physician’s notes, is a strong positive underwriting factor.

Maintain Regular Specialist Follow-Ups — Ongoing care with a hepatologist or gastroenterologist showing stable, monitored disease is essential. Documenting regular surveillance (HBV DNA tests, HCV RNA confirmations post-SVR, annual LFTs) demonstrates responsible management.

Work with a Specialist Broker — Hepatitis underwriting varies widely between carriers, especially for post-SVR Hep C and chronic Hep B carriers with normal LFTs. Only a specialist broker who informally shops your profile across 10–15 carriers — without triggering formal applications — can identify which carrier offers the best available rate for your specific lab history. Learn more about how TIB works.

Have Hepatitis B or C? Let’s Find the Right Carrier.

Hepatitis underwriting is highly individualized — especially for post-SVR Hep C. We informally shop your profile across 10–15 top-rated carriers to find the best available rate, without triggering formal applications or impacting your insurability.

📞 Call 1-888-972-0024
Get an Instant Quote →

Browse All High-Risk Conditions

Understanding Your Rating:
Life Insurance Risk Classifications |
Table Ratings Explained (B–J) |
Flat Extra Ratings

Authoritative Resources: Life insurance underwriting practices are regulated by the NAIC. Insurers may check your health history through the MIB Group — you can request your free annual MIB report at mib.com.

Frequently Asked Questions

Can I get life insurance with hepatitis C after successful treatment?

Yes, and increasingly on competitive terms. Hepatitis C cured with direct-acting antivirals (DAAs) like Harvoni, Mavyret, or Epclusa and showing sustained virologic response (SVR) for 12 or more weeks is now insurable at Standard to Standard Plus rate classes at most carriers. Some carriers will even extend Preferred rates after 2 to 5 years of sustained cure with normal liver function tests and no evidence of fibrosis or cirrhosis. This is a dramatic improvement from a decade ago when HCV was often a decline.

How is hepatitis B underwritten for life insurance?

Hepatitis B underwriting depends on whether the infection is acute, chronic inactive (carrier state), or chronic active. Resolved hepatitis B with positive surface antibody and negative surface antigen is typically treated as no rating. Inactive chronic HBV with normal liver enzymes, undetectable or low viral load, and no evidence of liver damage often qualifies for Standard to Table 2 rates. Active chronic hepatitis B with elevated viral load, abnormal enzymes, or evidence of fibrosis typically results in Table 2 through Table 6 ratings depending on severity and treatment status.

What tests do underwriters need for hepatitis life insurance applications?

For hepatitis C: most recent HCV antibody, HCV RNA (viral load), treatment history with DAA regimen, and documentation of sustained virologic response. For hepatitis B: surface antigen (HBsAg), surface antibody (anti-HBs), core antibody (anti-HBc), e-antigen status, HBV DNA viral load, and ALT/AST levels. Both require recent liver function tests, and for applicants with longer disease duration, either a FibroScan, liver biopsy, or FIB-4 index calculation to rule out significant fibrosis or cirrhosis.

Does cirrhosis from hepatitis disqualify me from life insurance?

Not necessarily, but it significantly narrows options. Compensated cirrhosis with stable liver function, no history of decompensation (ascites, variceal bleeding, encephalopathy), and a MELD score under 10 may qualify for Table 4 through Table 8 ratings at specialized carriers. Decompensated cirrhosis or MELD scores above 15 typically result in declines at traditionally underwritten carriers. Guaranteed issue policies remain available without liver testing, and some simplified issue products may accept compensated cirrhosis.

How do carriers view the mode of hepatitis transmission during underwriting?

Transmission history can affect underwriting beyond the hepatitis diagnosis itself. Transmission via medical procedures, blood transfusions before 1992, or vertical (mother-to-child) transmission is viewed neutrally. Transmission through IV drug use raises separate underwriting questions about substance use history — carriers will want documentation of sustained sobriety, typically 5 or more years, before offering favorable rates. Sexual transmission is generally underwritten neutrally with attention paid to any co-infections.